Lamellar Biomedical is an innovative biotechnology company developing our proprietary LAMELLASOME™ based therapies to transform the treatment of complex and rare lung disorders, either as biologically active products in their own right or by delivering active payloads. Along with our in-house research and development team, we are collaborating with world-renowned institutions and universities to develop therapeutics that capitalise on the unique properties of LAMELLASOME™ formulations that protect lung tissues. Lamellar’s lead products are: IPF-Lamellasome: abates pulmonary fibrosis by reducing both myofibroblasts and collagen production. IPF-Lamellasome has the potential to become the first line therapy and the new standard of care in the treatment of Idiopathic Pulmonary Fibrosis (IPF) IPF. Muco-ease: increases the fluidity of thickened human mucus and may slow disease progression in mild and moderate Cystic Fibrosis (CF) by improving mucociliary clearance Lamellasome treatment for COVID-19 intended to prevent or mitigate progression of respiratory symptoms to pneumonitis and ARDS, promoting survival ad potentially protecting lungs from fibrotic sequelae of survivors These therapies are based on LAMELLASOME™ therapies’ abilities to: Reduce inflammatory responses in pulmonary tissue. Interrupt the onset and progression of pulmonary inflammation, pneumonitis and the development of fibrosis. Modulate tissue surface tension, moisture retention and lubrication.